10P - Down-regulation of ERCC1 by EGFR-TKI improves platinum-based chemotherapy efficacy for non-small cell lung cancer (NSCLC)

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Non-Small-Cell Lung Cancer, Metastatic
Pathology/Molecular Biology
Translational Research
Presenter Hio Teng Cheong
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors H.T. Cheong1, C.W.C. Hui1, F. Xu2, T.S.K. Mok1, C.H. Wong1
  • 1Clinical Oncology, State Key Laboratory In Oncology In South China, The Chinese University of Hong Kong, NA - HONG KONG/HK
  • 2Medical Oncology, Sun-Yat Sen University Cancer Center, Guangzhou/CN


Platinum-based chemotherapy (Chemo) is the standard first line treatment for patients with EGFR wild type while EGFR TKI is the standard for patients with the mutation. FASTACT-2 (Wu et al Lancet Oncology 2013) compared intercalated Chemo and EGFR-TKI with Chemo, and subgroup biomarker studies showed that patients with EGFR wild type and positive ERCC1 attained longer progression free survival and overall survival. We postulate that EGFR TKI down-regulates ERCC1 expression in wild type EGFR NSCLC cells, thus enhances the chemotherapy efficacy.